Molecular Profile Detail

Profile Name ALK negative
Gene Variant Detail

ALK negative (loss of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK negative anaplastic large cell lymphoma predicted - sensitive Brentuximab vedotin Phase II Actionable In a Phase II trial (SGN-35), Adcetris (brentuximab vedotin) treatment resulted in complete remission in 57% (33/58), partial remission in 29% (17/58) of patients with relapsed or refractory systemic anaplastic large cell lymphoma, 72% (42/58) of the patients were ALK-negative (PMID: 22614995; NCT00866047). 22614995
ALK negative non-small cell lung carcinoma resistant CEP-28122 Preclinical - Cell line xenograft Actionable In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728). 22203728
ALK negative leukemia resistant CEP-28122 Preclinical - Cell culture Actionable In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728). 22203728
ALK negative lymphoma resistant CEP-28122 Preclinical - Cell culture Actionable In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728). 22203728
ALK negative colon carcinoma resistant CEP-28122 Preclinical - Cell line xenograft Actionable In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728). 22203728
Clinical Trial Phase Therapies Title Recruitment Status
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting
NCT03905135 Phase I Avelumab + rhIL-15 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Recruiting